Table 6.
Andersen-Gill regression model with the endpoint OS analysed on a per-protocol basis
| HR | 95 % CI | p value | |
|---|---|---|---|
| Genetic risk according to ELN | |||
| Favorable risk | 0.45 | 0.34–0.58 | <0.0001 |
| Intermediate-2 | 1.03 | 0.80–1.33 | 0.81 |
| Adverse risk | 1.88 | 1.51–2.34 | <0.0001 |
| s/t-AML | 1.33 | 1.05–1.68 | 0.019 |
| Gender (male) | 1.22 | 1.03–1.44 | 0.019 |
| Age (diff. 10 years) | 1.24 | 1.14–1.34 | <0.0001 |
| WBC (median-dichotomized)* | 1.51 | 1.26–1.81 | <0.0001 |
| Valproic acid | 1.35 | 1.10–1.67 | 0.005 |
| Allogeneic HCT in 1st CR | 0.71 | 0.58–0.88 | 0.001 |
| ATRA | 0.81 | 0.69–0.96 | 0.017 |
Variables excluded after limited backward selection in the order of their exclusion: DNMT3A mutational status (p = 0.87), ASXL1 mutational status (p = 0.70), RUNX1 mutational status (p = 0.61), FlT3-tKd (p = 0.53), IDH2 mutational status (p = 0.35), IDH1 mutational status (p = 0.34) and age (p = 0.08)
*The median WBC of the whole cohort was 12.7 G/L reference group intermediate-1